Home    Back

Terazosin    (DrugBank: Terazosin)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease2

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04386317
(ClinicalTrials.gov)		November 1, 202024/4/2020Terazosin Effect on Cardiac Changes in Early Parkinson's DiseaseThe Effect of a1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's DiseaseREM Sleep Behavior Disorder;Pre-motor Parkinson's Disease;Symptomatic Parkinson DiseaseDrug: TerazosinCedars-Sinai Medical CenterNULLRecruiting25 Years85 YearsAll15Phase 2United States
2NCT03905811
(ClinicalTrials.gov)		September 24, 20191/4/2019Terazosin for Parkinson's DiseaseA Pilot Study of Terazosin for Parkinson's DiseaseParkinson DiseaseDrug: Terazosin 5 MG;Drug: Placebo oral capsuleJordan SchultzUniversity of IowaEnrolling by invitation40 Years90 YearsAll20Phase 1;Phase 2United States